Rocbrutinib plus chemoimmunotherapy led to complete responses in patients with untreated B-cell lymphomas.
News|Articles|March 26, 2026
Multidisciplinary Breast Cancer Conversations Raise Insightful Questions for Clinical Practice Applications
Author(s)Ashling Wahner
Fact checked by: Riley Kandel
Oncology experts ask and answer multidisciplinary questions based on presentations from the 43rd Annual Miami Breast Cancer Conference.
Advertisement
Advertisement
The
Related to this article
See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.
A post hoc analysis of SPEARHEAD-1 found that MAGE-A4 H-score was independently tied to response and progression-free survival, whereas baseline tumor burden was tied to overall survival.
The IL-12–expressing self-replicating mRNA STX-001 showed a favorable therapeutic window at 100 µg, with regression in both injected and non-injected lesions.
Most of the survival time accrued with RP1 plus nivolumab in the IGNYTE trial was spent in good health among patients with advanced melanoma after anti–PD-1 therapy.
VET3-TGI produced responses in injected and non-injected lesions without dose-limiting toxicities in the phase 1/1b STEALTH-001 trial.
IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.
VGX-3100 met its composite primary end point in the phase 3 HPV-303CHN trial, supporting a nonsurgical treatment approach for HPV-16/18–associated cervical HSIL.
Advertisement
Advertisement